Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — TRxADE HEALTH — Q3 2022 Earnings Presentation
15 slides from Scienture's earnings presentation, Nov 7, 2022
Slide 1: NASDAQ:MEDS
NASDAQ:MEDS
Slide 2: Safe Harbor Statement
Safe Harbor Statement a ee The information set forth herein contains forward-looking statements within the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solel
Slide 3: About TRxADE HEALTH, INC.
About TRXADE HEALTH, INC. TRXxADE is a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. * Market Leader: Operates one of the largest technology market
Slide 4: Divisions of TRxADE HEALTH
Divisions of TRXADE HEALTH Pharmaceutical Marketplaces (With Supporting B2B + @IR NUM RY Drow Supplier-Pharmacy Marketplace Platform Manufacturer-Distributor Camis, Marketplace Platform PHARMACY Rx Distributor 1) Pie slices not representative of revenue mix between subsidiaries Supporting Subsidiari
Slide 5: TRxADE Marketplace
TRXADE Marketplace Independent Pharmacy and Clinics Our B2B Pharmaceutical Supply Chain Platform Footprint U.S. Pharmaceutical Industry?? * Projected $685B per year industry size by 2023 and growing; Over 65,000 Growth Pal pharmacy facilities Opportunity seks * Approximately 9 out of 10 Americans li
Slide 6: TRxADE Marketplace
TRXADE Marketplace Trxade.com (Distributor Pharmaceutical Supply Chain Platform) Our Marketplace Solution: *TRxADE’s exchange platform offers a clear and concise interface that allows over 14,100+ registered members in 50 states to analyze “up- to-the-minute” supply & pricing from multiple pharma su
Slide 7: Selected Operational Metrics
Selected Operational Metrics TRxADE Platform Our marketplace has over 72 national and regional pharmaceutical suppliers providing over 120,000 branded and generic drugs, including over the counter drugs and drugs available for purchase by pharmacists. Metrics for the three-month period ending Septem
Slide 8: Marketplace User Supporting Divisions
Marketplace User Supporting Divisions HEALTH v BONUM Bonum Health Tele Health Company offers individual and Employer sponsored patients access to certified medical providers 24/7/365 in 50 states * Focus on uninsured and underinsured patients * Has Partnerships with 1,000+ Retail chain and independe
Slide 9: Selected Financials
Selected Financials * High Margin: Revenue from transaction fees on marketplace platform (Credit Card/PayPal model) does not include the drugs value (over $100M annually), hence “tech like margins” * Built-Out Platform: 14,100+ registered members with continued platform development requiring minimal
Slide 10: Management
10 Management Suren Ajjarapu, Chairman of the Board and Chief Executive Officer Mr. Ajjarapu has served as Chairman of the Board, Chief Executive Officer and Secretary since our acquisition of Trxade Group, Inc., a Nevada corporation (“TRxADE Nevada”) (our predecessor company) on January 8, 2014, an
Slide 11: Key Takeaways
ia] Key Takeaways NASDAQ:MEDS TRXADE is a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. A Tech Focused Healthcare Services Company * Market Leader:
Slide 12: Contact Us
12 Contact Us TRxADE HEALTH, INC. 2420 Brunello Trace Lutz , FL 34558 (800) 261-0281 www.trxadehealth.com @TRADE
Slide 13: Appendix: Consolidated Balance Sheet
Appendix: Consolidated Balance Sheet (Unaudited) TRxADE HEALTH, INC Consolidated Balance Sheets September 30, 2022 and December 31, 2021 Assets Current Assets cash Accounts receivable, net Inventory Prepaid assets Other receivables Total Curent Assets Property plant and equipment, net 63.036 Intangi
Slide 14: Consolidated Statement of Operations
‘TRxADE HEALTH, INC. Consolidated Statement of Operations For the Three and Nine months Ended September 30, 2022 and 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues S 2400311 $ 2,550.06 S$ 8919, s 7.501.535 Cost of Sales 998,320 1,269,005 5,010,704
Slide 15: Reconciliation of Net Income to Adj. EBITDA
Appendix: Reconciliation of Net Income to Adj. EBITDA* Reconciliation of Net Income(Loss) attributable to TRKADE HEALTH, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA* For the Three Months Ended September 30, For the Nine Months Ended September